Course of kidney parameters in HCV-MC patients according to the type of treatment
| Parameter . | Peg-IFN-α/ribavirin (n = 10) . | P . | RTX-Peg-IFN-α/ribavirin (n = 21) . | P . |
|---|---|---|---|---|
| CR of kidney involvement | 4 (40) | 17 (80.9) | .040* | |
| Creatininemia, μmol/L | ||||
| Baseline | 150.0 ± 30.6 | 217.5 ± 47.4 | ||
| EOF | 169.2 ± 44.2 | .28 | 136.9 ± 27.1 | .03 |
| GFR, mL/min | ||||
| Baseline | 58.0 ± 7.4 | 42.8 ± 5.8 | ||
| EOF | 59.5 ± 9.9 | .41 | 57.6 ± 4.5 | .01 |
| Daily proteinuria, g | ||||
| Baseline | 3.1 ± 0.9 | 3.5 ± 0.9 | ||
| EOF | 1.2 ± 0.5 | .046 | 0.35 ± 0.1 | < .001 |
| Hematuria, n (%) | ||||
| Baseline | 9 (90) | 19 (90.5) | ||
| EOF | 2 (20) | .043 | 2 (10.5) | < .001 |
| Parameter . | Peg-IFN-α/ribavirin (n = 10) . | P . | RTX-Peg-IFN-α/ribavirin (n = 21) . | P . |
|---|---|---|---|---|
| CR of kidney involvement | 4 (40) | 17 (80.9) | .040* | |
| Creatininemia, μmol/L | ||||
| Baseline | 150.0 ± 30.6 | 217.5 ± 47.4 | ||
| EOF | 169.2 ± 44.2 | .28 | 136.9 ± 27.1 | .03 |
| GFR, mL/min | ||||
| Baseline | 58.0 ± 7.4 | 42.8 ± 5.8 | ||
| EOF | 59.5 ± 9.9 | .41 | 57.6 ± 4.5 | .01 |
| Daily proteinuria, g | ||||
| Baseline | 3.1 ± 0.9 | 3.5 ± 0.9 | ||
| EOF | 1.2 ± 0.5 | .046 | 0.35 ± 0.1 | < .001 |
| Hematuria, n (%) | ||||
| Baseline | 9 (90) | 19 (90.5) | ||
| EOF | 2 (20) | .043 | 2 (10.5) | < .001 |
Except where indicated otherwise, values are mean ± SD and n (%).
CR indicates complete response; EOF, end of follow-up; and GFR, glomerular filtration rate.
P value was calculated using the Fisher exact test for comparison of CR of kidney involvement between the 2 therapy groups. Comparisons between baseline and end of follow-up values were tested using the MacNemar test or the Wilcoxon paired test.